A logical extension in vascular targeting is as a result the application of anti angiogenic and vascular disrupting therapies in concert. This probability has been supported by observations in preclinical tumor models. For illustration, the combination of VEGFR2 linked tyrosine kinase inhibition and Tumor VDA remedy was discovered to lead to marked improvements in treatment outcomes even in tumors demonstrating only a modest response to single agent remedy.

Reports in which the anti VEGF antibody bevacizumab was mixed with the